🇺🇸 FDA
Pipeline program

MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension

APHP240201

Phase 1 small_molecule active

Quick answer

MUNC13.4-CD34 suspension, MUNC13.4-T3 suspension for Familial Hemophagocytic Lymphohistiocytosis (FHL) is a Phase 1 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Familial Hemophagocytic Lymphohistiocytosis (FHL)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials